Inserm Transfert Initiative was among the investors in a $12.3m funding round for Aelis Farma, which is working on a new class of drugs for cognitive disorders.
Aelis Farma, a France-based drug developer spun out of Inserm, has raised €11m ($12.3m) in a funding round backed by the research institute’s tech transfer arm, Inserm Transfert Initiative.
The round also included regional funds ACI, Naco and Aelis Innovation, the latter managed by Irdi Soridec Gestion, as well as public investment bank Bpifrance and the regional government of Région Nouvelle Aquitaine.
Founded in 2014, Aelis Farma is working on a new class of drugs – CB1 signalling…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
